New York, NY -- (ReleaseWire) -- 01/30/2013 --Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) stock is at $9.32, up 11.44 percent from its previous close of $8.36. The stock opened the session at $8.72 and touched its highest price point at $9.90. Keryx Biopharmaceuticals stock’s lowest price point for the session stood at $7.92. The stock is likely to maintain its bullish trend in the near term and medium term. Keryx Biopharmaceuticals may touch $9.55 level in the coming trading sessions.
The company announced its new public offering of $55 million. Keryx Biopharmaceuticals has appointed JP Morgan as its book running manager for the offering. The company is based out of New York.
Find out how this announcement could benefit KERX here:
Boston Scientific Corporation (NYSE:BSX) traded in the range of $7.10 and $7.38 during its latest trading session. The stock had opened at $7.12 and is at $7.32, up 3.24 percent from its previous close of $7.10. Boston Scientific recorded the volume of 25.385 million shares. Its average daily trading volume stands at 16.819 million shares. Its MACD chart shows bullish trend and the stock may go as up to $7.56 in the coming sessions. Its first support level stands at $7.04.
Boston Scientific develops and markets medical devices. The company is based out of Massachusetts and it was formed in 1979.
Find out more on BSX here: http://www.wallstreetreport.net/market-scan/?symbol=BSX
WallStreetReport.net issues momentum alerts on stocks that can provide gains to day traders. WallStreetReport.net provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. WallStreetReport.net monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals WallStreetReport.net is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the WallStreetReport.net newsletter and receiving alerts from a Pro-Active team of researchers. Wall Street Report believes traders should have a chance at successfully trading Penny Stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.WallStreetReport.net
WallStreetReport.net is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit WallStreetreport.Net website, for complete risks and disclosures.
BlueLys, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.
WALL STREET REPORT